Insilico Medicine (03696) announced that on November 17, 2026, it spent HK$12.608 million to repurchase 369,000 shares.
On November 17, 2026, the company also issued 44,400 shares upon the exercise of share options under its pre-IPO equity incentive plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments